Skip to main content

MHRA safety warning for Roche Accu-Chek Insight insulin pump and NovoRapid PumpCart prefilled insulin cartridge

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a safety warning about the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump.
JDRF logo placeholder for author profile picture
Kate Lawton 26 May 2022

Medicines & Healthcare Products Regulatory Agency

Safety warning

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a safety warning about the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump.

This follows concerns raised about cracked cartridges and insulin leaks.

The MHRA is advising healthcare professionals to contact people who are affected by 26 November 2022.

In the meantime, the agency has provided these recommendations for users of the pump and insulin cartridges:

  • Check the pump and cartridge regularly for damages, for example cracks or leakage. If you smell insulin (a strong antiseptic chemical smell) this could also indicate a leakage.
  • Do not use the cartridge if cracks or leakage are seen or if the cartridge was dropped. Follow the instructions of your Accu-Chek Insight user manual for replacing a cartridge and for cleaning the cartridge compartment in the insulin pump.
  • During the day and before going to sleep please carefully check that your insulin pump is delivering insulin and there are no leakages.
  • Never change treatment delivery methods without first consulting a relevant healthcare professional.
  • Failure of insulin delivery due to leakage may not result in an alert notification from the insulin pump and cracks and leakages may not always be visible. You should check blood glucose levels multiple times throughout your day whilst using pumps.
  • Tell your healthcare professional immediately if you suspect a problem with your insulin delivery.

MRHA statement in full

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight insulin pump system following concerns raised about cracked cartridges and insulin leaks.

Patients are being asked to check the pre-filled glass insulin cartridge for cracks prior to use. The cartridge should not be used if it has been dropped even if no cracks are visible. Closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges.

The device, which releases the insulin your body needs throughout the day and night, comprises a pump, tube, battery and a pre-filled glass insulin cartridge. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. However, leakages also occurred in cases where no cracks in the cartridge were visible. In some patients, there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis (a serious complication of diabetes when the body produces high levels of blood acids called ketones).

Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate.

Key patient recommendations

Key patient recommendations are:

  • Check the pump and cartridge regularly for damages, for example cracks or leakage. If you smell insulin (a strong antiseptic chemical smell) this could also indicate a leakage.
  • Do not use the cartridge if cracks or leakage are seen or if the cartridge was dropped. Follow the instructions of your Accu-Chek Insight user manual for replacing a cartridge and for cleaning the cartridge compartment in the insulin pump.
  • During the day and before going to sleep please carefully check that your insulin pump is delivering insulin and there are no leakages.
  • Never change treatment delivery methods without first consulting a relevant healthcare professional.
  • Failure of insulin delivery due to leakage may not result in an alert notification from the insulin pump and cracks and leakages may not always be visible. You should check blood glucose levels multiple times throughout your day whilst using pumps.
  • Tell your healthcare professional immediately if you suspect a problem with your insulin delivery.

Dr June Raine, Chief Executive, Medicines and Healthcare products Regulatory Agency said: “For many patients with diabetes, insulin pumps are an important method of treatment and provide freedom and flexibility in the day to day management of their condition. Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight insulin pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage.

“We would like to reassure patients that the risk of leakage remains low when used in accordance with instructions and today’s safety recommendations. Patients should continue to use their insulin pump as recommended whilst they await contact from their healthcare professional regarding an alternative device.

“If you suspect a problem with your insulin pump, please seek medical advice immediately.”

Professor Partha Kar, National Specialty Advisor, Diabetes with NHS England and co-lead of Diabetes GIRFT with NHS Improvement said: “We are grateful to the MHRA for working closely with us on the issue of insulin pumps and any relevant safety concerns. We would encourage healthcare professionals to carefully review the National Patient Safety Alert and discuss with relevant patients the risks and appropriate mitigations as needed. We would remind patients that they should not change treatment methods without first consulting a relevant healthcare professional.”

Read the National Patient Safety Alert and advice for healthcare professionals here.

Related news

Read more
Hybrid closed loop technology
Type 1 technology
19 December 2023

NICE Approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales

In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
Illustration of the hybrid closed loop technology system, funded as part of treatment research for type 1 diabetes by JDRF.
Type 1 technology
21 August 2023

NICE’s latest consultation on hybrid closed loop

As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.

Read more
A woman standing in a park using the Omnipod 5 system for type 1 diabetes
Type 1 technology
21 June 2023

Omnipod 5 becomes the latest hybrid closed loop system available in the UK

Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.